Corvus Pharmaceuticals, Inc.

NASDAQ:CRVS

Biotechnology

Healthcare
$10.19 -1.58%

-$0.19 today

Market cap
$859.56M
Beta
0.84
P/E (TTM)
-24.1
EPS (TTM)
-$0.49
52W Low $3.55High $26.95

Volume 0.99M

Average 1.49M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$32.80M

FY 2025 · Annual

Investing Cash Flow

-$7.80M

FY 2025 · Annual

Financing Cash Flow

$36.43M

FY 2025 · Annual

-25.7% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(43.24M)(41.31M)(27.03M)(62.29M)(15.28M)
Depreciation & Amortization460K367K151K85K105K
Deferred Income Tax00000
Stock-Based Compensation4.23M2.69M2.15M3M5.33M
Change in Working Capital(3.24M)1.41M(3.59M)(1.65M)3.58M
Accounts Receivables(507K)(81K)562K(49K)38K
Inventory00000
Accounts Payables(1.9M)411K(451K)1.06M(91K)
Other Working Capital(827K)1.08M(3.71M)(2.66M)3.63M
Other Non-Cash Items5.07M9.81M4.39M35.43M(26.53M)
Operating Cash Flow(36.72M)(27.02M)(23.94M)(25.42M)(32.8M)
Capital Expenditures(5K)(269K)(34K)0(174K)
Acquisitions (Net)(21.57K)22K05K0
Purchases of Investments(9.36M)(66.19M)(47.05M)(70.12M)(91.75M)
Sales of Investments30.92M43.16M62.62M42.63M84.13M
Other Investing Activities21.57K0000
Investing Cash Flow21.56M(23.28M)15.54M(27.48M)(7.8M)
Debt Repayment00000
Common Stock Issued60.94M07.84M16.41M36.43M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.22M012K32.62M0
Financing Cash Flow62.16M07.86M49.03M36.43M
Effect of Forex Changes00000
Net Change in Cash47M(50.3M)(539K)(3.88M)(4.16M)
Free Cash Flow(36.72M)(27.29M)(23.97M)(25.42M)(32.97M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$15.3M
+ D&A$105.0K
+ Stock-Based Comp$5.3M
+ Deferred Tax$0
+ Working Capital$3.6M
- Other Non-Cash-$26.5M
= Operating Cash Flow-$32.8M
- Capex-$174.0K
= Free Cash Flow-$33.0M

Analysis

FY2025 free cash flow is -$33.0M. FCF conversion is 215.7% of net income. Operating cash flow was -$32.8M, with capex of -$174.0K. The largest bridge item is Other Non-Cash at -$26.5M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
4Statement of changes in beneficial ownershipNov 13, 2026
SC 13GSC 13G filingNov 10, 2026
10-QQuarterly reportNov 5, 2026
8-KCurrent reportNov 5, 2026
SC 13GSC 13G filingAug 7, 2026

Does CRVS generate free cash flow?

Corvus Pharmaceuticals, Inc. (CRVS) generated -$32.97M of free cash flow in fiscal 2025.

How much operating cash flow does CRVS produce?

Operating cash flow was -$32.80M, before capital expenditures of $174,000.00.